Immunogenicity and Protection from a Single Dose of Internationally Available Killed Oral Cholera Vaccine

A Systematic Review and Metaanalysis

Anna Lena Lopez, Jacqueline Deen, Andrew Azman, Francisco J. Luquero, Suman Kanungo, Shanta Dutta, Lorenz Von Seidlein, David Allen Sack

Research output: Contribution to journalReview article

Abstract

In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efcacy and effectiveness) conferred by a single OCV dose against cholera. Te metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, afer an OCV frst dose. Te estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufcient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

Original languageEnglish (US)
Pages (from-to)1960-1971
Number of pages12
JournalClinical Infectious Diseases
Volume66
Issue number12
DOIs
StatePublished - Jun 1 2018

Fingerprint

Cholera Vaccines
Cholera
Vaccines
Computer Security
Sanitation
Water Supply
Disease Outbreaks

Keywords

  • cholera
  • cholera vaccine
  • oral cholera vaccine
  • Vibrio cholera

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Immunogenicity and Protection from a Single Dose of Internationally Available Killed Oral Cholera Vaccine : A Systematic Review and Metaanalysis. / Lopez, Anna Lena; Deen, Jacqueline; Azman, Andrew; Luquero, Francisco J.; Kanungo, Suman; Dutta, Shanta; Von Seidlein, Lorenz; Sack, David Allen.

In: Clinical Infectious Diseases, Vol. 66, No. 12, 01.06.2018, p. 1960-1971.

Research output: Contribution to journalReview article

Lopez, Anna Lena ; Deen, Jacqueline ; Azman, Andrew ; Luquero, Francisco J. ; Kanungo, Suman ; Dutta, Shanta ; Von Seidlein, Lorenz ; Sack, David Allen. / Immunogenicity and Protection from a Single Dose of Internationally Available Killed Oral Cholera Vaccine : A Systematic Review and Metaanalysis. In: Clinical Infectious Diseases. 2018 ; Vol. 66, No. 12. pp. 1960-1971.
@article{f6744b00eb9e4be0bb3069f42e2eb90f,
title = "Immunogenicity and Protection from a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis",
abstract = "In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efcacy and effectiveness) conferred by a single OCV dose against cholera. Te metaanalysis showed that an estimated 73{\%} and 77{\%} of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, afer an OCV frst dose. Te estimates of single-dose vaccine protection from available studies are 87{\%} at 2 months decreasing to 33{\%} at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufcient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.",
keywords = "cholera, cholera vaccine, oral cholera vaccine, Vibrio cholera",
author = "Lopez, {Anna Lena} and Jacqueline Deen and Andrew Azman and Luquero, {Francisco J.} and Suman Kanungo and Shanta Dutta and {Von Seidlein}, Lorenz and Sack, {David Allen}",
year = "2018",
month = "6",
day = "1",
doi = "10.1093/cid/cix1039",
language = "English (US)",
volume = "66",
pages = "1960--1971",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Immunogenicity and Protection from a Single Dose of Internationally Available Killed Oral Cholera Vaccine

T2 - A Systematic Review and Metaanalysis

AU - Lopez, Anna Lena

AU - Deen, Jacqueline

AU - Azman, Andrew

AU - Luquero, Francisco J.

AU - Kanungo, Suman

AU - Dutta, Shanta

AU - Von Seidlein, Lorenz

AU - Sack, David Allen

PY - 2018/6/1

Y1 - 2018/6/1

N2 - In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efcacy and effectiveness) conferred by a single OCV dose against cholera. Te metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, afer an OCV frst dose. Te estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufcient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

AB - In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efcacy and effectiveness) conferred by a single OCV dose against cholera. Te metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, afer an OCV frst dose. Te estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufcient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

KW - cholera

KW - cholera vaccine

KW - oral cholera vaccine

KW - Vibrio cholera

UR - http://www.scopus.com/inward/record.url?scp=85048005104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048005104&partnerID=8YFLogxK

U2 - 10.1093/cid/cix1039

DO - 10.1093/cid/cix1039

M3 - Review article

VL - 66

SP - 1960

EP - 1971

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -